Key result
Vasopressors exacerbate pre-existing PH in LHD by increasing pulmonary blood volume and LAP.
Why the study?
The interaction between vasopressors and pulmonary hypertension due to left heart disease is often overlooked, posing significant risks of exacerbating pulmonary congestion and causing diagnostic confusion with pulmonary arterial hypertension.
Vasopressors can induce passive pulmonary hypertension and exacerbate pre-existing pulmonary hypertension due to left heart disease, highlighting the need for careful hemodynamic management and volume control in these patients.
Answers are grounded in this paper and cite their sources.
May warrant cautious vasopressor use in left heart disease-associated pulmonary hypertension; leaves open prospective hemodynamic validation.
Pulmonary hypertension due to left heart disease (PH-LHD) is the most common form of pulmonary hypertension (PH), accounting for 65–80% of cases, and is associated with significant morbidity and mortality. PH-LHD is traditionally considered a passive condition, primarily driven by elevated left heart pressure, which increases pulmonary venous pressure. However, vasopressors, such as phenylephrine, frequently used in critical care to enhance vascular tone, can induce another form of passive PH. This vasopressor-induced PH shares hemodynamic similarities with PH-LHD, characterized by increased pulmonary blood volume and left atrial pressure, and exerts additive effects on pre-existing PH-LHD, exacerbating pulmonary congestion and worsening clinical outcomes. The interaction between vasopressors and PH-LHD is often overlooked, yet it poses significant risks, particularly in patients with heart failure. This review explores the pathophysiology of passive PH-LHD, the mechanisms of vasopressor-induced PH, and their additive effects. We also highlight the challenges in diagnosing passive PH, which is frequently misclassified as pulmonary arterial hypertension (PAH), leading to inappropriate treatment and potential harm. Current therapeutic strategies, such as diuretics and blood volume management, are discussed as potential approaches to mitigate these effects. Improved understanding of these mechanisms is crucial for optimizing treatment and reducing morbidity and mortality. Future research is needed to develop targeted therapies and improve outcomes for patients with PH-LHD and vasopressor-induced PH.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2025) conducted a review in Pulmonary hypertension due to left heart disease (PH-LHD). Vasopressors was evaluated. Vasopressors induce a passive form of pulmonary hypertension that exacerbates pre-existing pulmonary hypertension due to left heart disease by increasing pulmonary blood volume and left atrial pressure.
Synapse has enriched 10 related papers. Consider them for comparative context: